Study explains how part of the nucleolus evolved
A single protein can self-assemble to build the scaffold for a biomolecular condensate that makes up a key nucleolar compartment.
A single protein can self-assemble to build the scaffold for a biomolecular condensate that makes up a key nucleolar compartment.
MIT PhD student Kathrin Kajderowicz is studying how hibernation-like states could pave the way for new hypothermic therapies.
SMART researchers find the enzyme RlmN, which directly senses chemical and environmental stresses, can be targeted in drug development.
MIT researchers find timing and dosage of DNA-damaging drugs are key to whether a cancer cell dies or enters senescence.
The device detects the same molecules that cell receptors do, and may enable routine early screening for cancers and other diseases.
Whitehead Institute researchers find many transcription factors bind RNA, which fine-tunes their regulation of gene expression, suggesting new therapeutic opportunities.
Mathias Kolle’s color-changing materials take inspiration from butterflies and mollusks.
A new technology called RIBOmap can give researchers valuable insight into how protein production in animal and human tissue is altered in disease.
A new approach for identifying significant differences in gene use between closely-related species provides insights into human evolution.
Scientists find a protein common to flies and people is essential for supporting the structure of axons that neurons project to make circuit connections.
MIT researchers characterize gene expression patterns for 22,500 brain vascular cells across 428 donors, revealing insights for Alzheimer’s onset and potential treatments.
When astrocyte function is disrupted, neurons in the brain’s motor cortex struggle to execute and refine motion, a new study in mice shows.
With further development, the programmable system could be used in a range of applications including gene and cancer therapies.
Ming Guo seeks connections between a cell’s physical form and its biological function, which could illuminate ways to halt abnormal cell growth.
The associate professor of MechE reflects on how his company, Kytopen, has grown and shifted focus in developing safer immunotherapies.